| Literature DB >> 28462379 |
Minna M Wieck1,2, Christopher R Schlieve1,2, Matthew E Thornton3, Kathryn L Fowler1, Mubina Isani1,2, Christa N Grant1,2, Ashley E Hilton4, Xiaogang Hou1, Brendan H Grubbs3, Mark R Frey1,5, Tracy C Grikscheit1,2,4.
Abstract
BACKGROUND & AIMS: For patients with short-bowel syndrome, intestinal adaptation is required to achieve enteral independence. Although adaptation has been studied extensively in animal models, little is known about this process in human intestine. We hypothesized that analysis of matched specimens with and without luminal flow could identify new potential therapeutic pathways.Entities:
Keywords: Calorie Restriction; Enteric Nutrition; ISC, intestinal stem cell; Intestinal Stem Cell; LGR5; Mechanoluminal Flow; NEC, necrotizing enterocolitis; PCR, polymerase chain reaction; SBS, short-bowel syndrome; STAT3, signal transducer and activator of transcription 3; Small Intestine; Wnt, wingless-related integration site; mRNA, messenger RNA; qPCR, quantitative polymerase chain reaction
Year: 2017 PMID: 28462379 PMCID: PMC5403975 DOI: 10.1016/j.jcmgh.2016.12.008
Source DB: PubMed Journal: Cell Mol Gastroenterol Hepatol ISSN: 2352-345X
Figure 1( The proximal fed portion of the small intestine receives mechanoluminal stimulation through enteric feeding. The distal unfed portion of diverted small intestine does not see mechanoluminal stimulation for a minimum period of 7 weeks. The length of intestinal resection ranged from 0 to 20 cm in length, with an average resection of 5 cm. Upon ileostomy takedown and anastomosis, samples procured for the study were obtained within 1–2 cm proximal to the stoma in fed intestine and 1–2 cm distal to the diverted unfed pouch (red dotted boxes).
Patient Characteristics
| Patient | Sex | Diagnosis | Gestational age, | Birth weight, | Age at resection, | Weight at resection, | Location of resection | Amount resected, | Diversion duration, | Nutrition after resection | Age at reversal, | Weight at reversal, | Weight gain, | Nutrition after reversal | Ostomy complications | Postreversal complications | Comorbidities |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | F | NEC | 25 4/7 | 0.770 | 2.0 | 0.750 | Ileum: 7.5 cm from ICV | 4 | 9.0 | TPN + formula until ostomy reversal | 2 | 1.785 | 138.00 | TPN | None | Anastomotic leak | CLD, IVH, ROP, cholestasis of PN |
| B | F | FIP | 24 | 0.700 | 2.5 | 0.835 | Ileum: 5.0 cm from ICV | 2 | 19.0 | TPN + formula first 6 wk, then full formula | 5 | 2.93 | 250.90 | TPN until POD 5, formula started POD 6 | Peristomal hernia without obstruction | None | CLD, IVH, ROP |
| C | F | FIP | 24 5/7 | 0.705 | 5.0 | 1.040 | Ileum: 15 cm from ICV | 7 | 13.5 | TPN + formula/BM until ostomy reversal | 4.5 | 3.20 | 207.69 | TPN until POD 23, formula started POD 7 | None | Ileus | CLD, BPD, anemia, PS, ROP |
| D | F | FIP | 28 | 0.810 | 1.0 | 0.800 | Ileum: 45 cm from ICV | 4 | 11.5 | TPN + formula/BM until ostomy reversal | 2 | 2.655 | 231.88 | TPN until POD 27, formula started POD 18 | Peristomal abscess | Ileus | CLD, PDA, anemia |
| E | M | NEC | 26 3/7 | 0.900 | 1.5 | 0.900 | Mid-ileum | 1.5 | 31.0 | TPN + formula first 4 wk, then full formula | 7.5 | 5.1 | 466.67 | TPN POD 8–11, | None | None | PDA, ROP, GERD, apnea, anemia |
| F | M | FIP | 26 | 0.810 | 1.0 | 0.810 | Mid-ileum | 9 | 15.0 | TPN + formula until ostomy reversal | 4 | 2.675 | 230.25 | TPN until POD 15, formula started POD 10 | None | Wound infection | Twin, CLD, PDA, cholestasis of PN |
| G | F | NEC | 35 | 2.240 | 4.0 | 3.550 | Ileum: 15 cm from ICV | 20 | 7.0 | TPN + formula until ostomy reversal | 2.5 | 3.62 | 1.97 | TPN until POD 14, formula started POD 5 | Peristomal hernia without obstruction | None | Twin, rotavirus, thrombosis |
| H | M | FIP | 25 1/7 | 0.655 | 1.0 | 0.680 | Ileum just proximal to ICV | 0 | 13.0 | TPN + fortified BM/formula until ostomy reversal | 3 | 2.415 | 255.15 | TPN until POD 14, formula started POD 7 | None | Fulminant pneumatosis | CLD, meningitis, sepsis, osteopenia |
| I | M | NEC | 25 | 0.760 | 1.0 | 0.900 | Ileum: 2 cm from ICV | 4 | 44.0 | TPN + formula first 6 wk, then full formula | 10 | 6.54 | 626.67 | TPN until POD 74, formula started POD 37 | Stomal retraction | Adenovirus diarrhea | CLD, PDA |
| J | M | FIP | 26 | 0.650 | 1.5 | 0.685 | Ileum: 22 cm from ICV | 2 | 16.0 | TPN + BM until ostomy reversal | 4 | 2.655 | 287.59 | TPN until POD 11, BM started POD 5 | Peristomal skin breakdown | None | CLD, IVH, anemia, osteopenia, ROP |
| K | M | FIP | 25 1/7 | 0.885 | 1.5 | 0.995 | Ileum | 0 | 11.5 | TPN + BM for first 4 wk, then full BM | 13 | 3.012 | 202.71 | TPN until POD 22, BM started POD 7 | EC fistula, peristomal skin breakdown | None | CLD, ROP |
| L | M | FIP | 22 6/7 | 0.487 | 1.0 | 0.470 | Ileum | 8 | 19.0 | TPN + BM until ostomy reversal | 20 | 2.95 | 527.66 | TPN until POD 18, BM started POD 10 | None | Urosepsis, pneumonia | PDA, sepsis, ROP |
| M | F | FIP | 24 5/7 | 0.705 | 5.0 | 1.040 | Ileum | 7 | 13.5 | TPN + formula/BM until ostomy reversal | 8 | 3.20 | 207.69 | TPN until POD 26, formula started POD 7 | None | Ileus | CLD, BPD, ROP, anemia, PS |
| N | M | NEC | 38 2/7 | 3.625 | 0.5 | 4.015 | Ileum | 4 | 48 | TPN + formula for first 2 wk, then full formula until ostomy reversal | 11 | 7.3 | 81.82 | Formula started POD 5 | Peristomal skin breakdown | None | Trisomy 21, HD, PDA, ASD |
| O | F | NEC | 23 | 0.555 | 4.0 | 0.700 | Ileum just proximal to ICV | 15 | 18.5 | Intermittent TPN + formula until ostomy reversal | 5 | 3.185 | 355.00 | TPN until POD 5, formula started POD 5 | None | None | ROP |
NOTE. Patient characteristics were obtained from medical records on consented patients who met criteria for the study.
ASD, atrial septal defect; BM, breast milk; BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; EC, enterocutaneous; FIP, focal intestinal perforation; GERD, gastroesophageal reflux disease; HD, Hirschprung disease; ICV, ileocecal valve; IVH, intraventricular hemorrhage; PDA, patent ductus arteriosus; PN, parenteral nutrition; POD, postoperative day; PS, pulmonary stenosis; ROP, retinopathy of prematurity; TPN, total parenteral nutrition.
Top 100 Up- and Down-Regulated Genes in Unfed Small Intestine
| Gene name | Description | logFC | LR | Ensembl gene ID | |
|---|---|---|---|---|---|
| FMO1 | Flavin containing monooxygenase 1 | 1.935156001 | 74.80308156 | 5.20085E-18 | ENSG00000010932 |
| UPK3A | Uroplakin 3A (source: HGNC symbol) | 2.147520087 | 46.60854851 | 8.66813E-12 | ENSG00000100373 |
| CXCL5 | Chemokine (C-X-C motif) ligand 5 | -2.733639395 | 41.69682868 | 1.06582E-10 | ENSG00000163735 |
| RNF224 | Ring finger protein 224 | 1.839210925 | 41.87209741 | 9.74433E-11 | ENSG00000233198 |
| CYSRT1 | Cysteine-rich tail protein 1 | 1.720249115 | 39.9409415 | 2.61759E-10 | ENSG00000197191 |
| SLC5A12 | Solute carrier family 5 (sodium/monocarboxylate cotransporter), member 12 | 2.132807939 | 38.74458626 | 4.83048E-10 | ENSG00000148942 |
| SULT2A1 | Sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone-preferring, member 1 | 2.097488909 | 37.82205594 | 7.75006E-10 | ENSG00000105398 |
| MRO | Maestro | 1.848607121 | 36.97909256 | 1.19403E-09 | ENSG00000134042 |
| LINC01595 | Long intergenic nonprotein coding RNA 1595 | 2.165402806 | 36.06166015 | 1.91171E-09 | ENSG00000259108 |
| SHBG | Sex hormone-binding globulin | 1.738789918 | 35.47000772 | 2.59008E-09 | ENSG00000129214 |
| SLC23A1 | Solute carrier family 23 (ascorbic acid transporter), member 1 | 1.603537606 | 35.15428148 | .000000003 | ENSG00000170482 |
| SLC34A3 | Solute carrier family 34 (type II sodium/phosphate cotransporter), member 3 | 1.537065735 | 34.51159913 | 4.23719E-09 | ENSG00000198569 |
| PDZK1 | PDZ domain containing 1 | 1.585707896 | 34.29271495 | 4.74153E-09 | ENSG00000174827 |
| TREH | Trehalase (brush-border membrane glycoprotein) | 1.194202148 | 33.81359331 | 6.06536E-09 | ENSG00000118094 |
| SULT1C2 | Sulfotransferase family, cytosolic, 1C, member 2 | 1.907549377 | 33.14195314 | 8.56702E-09 | ENSG00000198203 |
| ENPP7 | Ectonucleotide pyrophosphatase/phosphodiesterase 7 | 1.300165718 | 32.59690058 | 1.13395E-08 | ENSG00000182156 |
| F7 | Coagulation factor VII (serum prothrombin conversion accelerator) | 1.780260275 | 31.79235485 | 1.71567E-08 | ENSG00000057593 |
| CYP4F2 | Cytochrome P450, family 4, subfamily F, polypeptide 2 | 1.683482981 | 31.31912349 | 2.18913E-08 | ENSG00000186115 |
| SLC13A1 | Solute carrier family 13 (sodium/sulfate symporter), member 1 | 2.538985085 | 30.81618591 | 2.83662E-08 | ENSG00000081800 |
| SLC5A9 | Solute carrier family 5 (sodium/sugar cotransporter), member 9 | 1.538317273 | 30.90810275 | 2.7054E-08 | ENSG00000117834 |
| PRKG2 | Protein kinase, cGMP-dependent, type II | 1.27808205 | 30.94340641 | 2.65663E-08 | ENSG00000138669 |
| RP11-798K3.2 | NA | 1.855803844 | 30.7019997 | 3.00855E-08 | ENSG00000259347 |
| FRMD1 | FERM domain containing 1 | 1.696220028 | 30.15783587 | 3.98275E-08 | ENSG00000153303 |
| NAALADL1 | N-acetylated α-linked acidic dipeptidase-like 1 | 1.672980254 | 30.09099621 | 4.12241E-08 | ENSG00000168060 |
| MS4A8 | Membrane-spanning 4-domains, subfamily A, member 8 | 1.779882861 | 29.92631817 | 4.4878E-08 | ENSG00000166959 |
| FADS6 | Fatty acid desaturase 6 | 1.921798418 | 29.9963597 | 4.32858E-08 | ENSG00000172782 |
| SLC7A9 | Solute carrier family 7 (amino acid transporter light chain, bo,+ system), member 9 | 1.481271455 | 29.75955747 | 4.89089E-08 | ENSG00000021488 |
| CDHR5 | Cadherin-related family member 5 | 1.515548333 | 29.50960252 | 5.56404E-08 | ENSG00000273572 |
| CEL | Carboxyl ester lipase | 1.634979875 | 28.99145378 | 7.26983E-08 | ENSG00000170835 |
| NAT8 | N-acetyltransferase 8 (GCN5-related, putative) | 2.675738291 | 28.71017357 | 8.4061E-08 | ENSG00000144035 |
| ATP13A4 | ATPase type 13A4 | 1.939358607 | 28.12477638 | 1.1374E-07 | ENSG00000127249 |
| UNC93A | Unc-93 homolog A ( | 1.601007557 | 28.04197919 | 1.18712E-07 | ENSG00000112494 |
| SLC2A2 | Solute carrier family 2 (facilitated glucose transporter), member 2 | 1.556431458 | 27.87085693 | 1.29688E-07 | ENSG00000163581 |
| TMIGD1 | Transmembrane and immunoglobulin domain-containing 1 | 1.967330736 | 27.70509208 | 1.4129E-07 | ENSG00000182271 |
| TFEC | Transcription factor EC | 1.321562424 | 27.57164133 | 1.51382E-07 | ENSG00000105967 |
| CUBN | Cubilin (intrinsic factor-cobalamin receptor) | 2.341955896 | 27.18194662 | 1.8518E-07 | ENSG00000107611 |
| SLC19A3 | Solute carrier family 19 (thiamine transporter), member 3 | 1.552887155 | 27.26057746 | 1.778E-07 | ENSG00000135917 |
| SMLR1 | Small leucine-rich protein 1 | 1.612876682 | 27.21140528 | 1.8238E-07 | ENSG00000256162 |
| NNMT | Nicotinamide N-methyltransferase | -1.472271231 | 26.94985142 | 2.08803E-07 | ENSG00000166741 |
| NAT8B | N-acetyltransferase 8B (GCN5-related, putative, gene/pseudogene) | 1.718975423 | 26.9959476 | 2.03882E-07 | ENSG00000204872 |
| SLC28A1 | Solute carrier family 28 (concentrative nucleoside transporter), member 1 | 1.407436527 | 26.62926909 | 2.46481E-07 | ENSG00000156222 |
| AC007325.2 | NA | 1.46829846 | 26.64878695 | .000000244 | ENSG00000277196 |
| GGT1 | γ-Glutamyltransferase 1 | 1.080943383 | 26.48751824 | 2.65246E-07 | ENSG00000100031 |
| TRPM6 | Transient receptor potential cation channel, subfamily M, member 6 | 1.828527681 | 26.32603584 | 2.88375E-07 | ENSG00000119121 |
| KHK | Ketohexokinase (fructokinase) | 1.251604031 | 26.35745455 | 2.83722E-07 | ENSG00000138030 |
| SLC6A4 | Solute carrier family 6 (neurotransmitter transporter), member 4 | 1.399303921 | 25.97462634 | 3.45934E-07 | ENSG00000108576 |
| SLC28A2 | Solute carrier family 28 (concentrative nucleoside transporter), member 2 | 2.441573348 | 25.9860024 | 3.43902E-07 | ENSG00000137860 |
| ENPP3 | Ectonucleotide pyrophosphatase/phosphodiesterase 3 | 1.084760034 | 26.01060946 | 3.39546E-07 | ENSG00000154269 |
| TMEM236 | Transmembrane protein 236 | 1.492276653 | 25.93225942 | 3.5361E-07 | ENSG00000148483 |
| NR1H4 | Nuclear receptor subfamily 1, group H, member 4 | 1.530681737 | 25.66165786 | 4.0683E-07 | ENSG00000012504 |
| COL2A1 | Collagen, type II, α 1 | 2.7427092 | 25.57237858 | 4.26095E-07 | ENSG00000139219 |
| DPEP1 | Dipeptidase 1 (renal) | 2.012092029 | 25.51498355 | .000000439 | ENSG00000015413 |
| SLC16A10 | Solute carrier family 16 (aromatic amino acid transporter), member 10 | 1.574547146 | 25.44844819 | 4.54363E-07 | ENSG00000112394 |
| CLIC5 | Chloride intracellular channel 5 [ | 1.133191008 | 25.28347044 | 4.94932E-07 | ENSG00000112782 |
| PRLR | Prolactin receptor | 1.441337236 | 25.30981848 | 4.88217E-07 | ENSG00000113494 |
| MCOLN3 | Mucolipin 3 | 1.595364418 | 25.21959734 | 5.11597E-07 | ENSG00000055732 |
| RP11-1193F23.1 | NA | 2.585443625 | 25.20976053 | 5.14213E-07 | ENSG00000279024 |
| PKIB | Sp8 transcription factor | 6.674019267 | 25.17393696 | 5.23854E-07 | ENSG00000164651 |
| MAMDC4 | MAM domain containing 4 | 1.277939128 | 24.86218203 | 6.15787E-07 | ENSG00000177943 |
| SLC3A1 | Solute carrier family 3 (amino acid transporter heavy chain), member 1 | 1.781625122 | 24.80772832 | 6.3343E-07 | ENSG00000138079 |
| PKIB | Protein kinase (cAMP-dependent, catalytic) inhibitor β | 1.549061572 | 24.60352117 | 7.04229E-07 | ENSG00000135549 |
| CYP3A4 | Cytochrome P450, family 3, subfamily A, polypeptide 4 | 1.922951569 | 24.62844524 | 6.9518E-07 | ENSG00000160868 |
| CDHR5 | Cadherin-related family member 5 | 1.430921311 | 24.46118573 | 7.5822E-07 | ENSG00000099834 |
| SOAT2 | Sterol O-acyltransferase 2 | 1.220274465 | 24.30393855 | 8.22707E-07 | ENSG00000167780 |
| SFRP5 | Secreted frizzled-related protein 5 | 1.289605732 | 24.05353528 | 9.36941E-07 | ENSG00000120057 |
| DAB1 | Dab, reelin signal transducer, homolog 1 | 1.317550733 | 24.100991 | 9.14132E-07 | ENSG00000173406 |
| LRRC19 | Leucine-rich repeat containing 19 | 1.489115345 | 24.05615315 | 9.35668E-07 | ENSG00000184434 |
| TYRP1 | Tyrosinase-related protein 1 | -1.664137392 | 23.96832679 | 9.79336E-07 | ENSG00000107165 |
| CCDC108 | Coiled-coil domain containing 108 | 2.035404412 | 23.98451824 | 9.71135E-07 | ENSG00000181378 |
| TRHDE-AS1 | TRHDE antisense RNA 1 | 2.045816171 | 23.98498662 | 9.70898E-07 | ENSG00000236333 |
| AQP7 | Aquaporin 7 | 1.601418775 | 23.74146929 | 1.10183E-06 | ENSG00000165269 |
| MYO7A | Myosin VIIA | 1.042545085 | 23.61253694 | 1.17817E-06 | ENSG00000137474 |
| SLC26A2 | Solute carrier family 26 (anion exchanger), member 2 | 1.088822376 | 23.62142755 | 1.17274E-06 | ENSG00000155850 |
| SLC30A2 | Solute carrier family 30 (zinc transporter), member 2 | 1.335008616 | 23.60508117 | 1.18275E-06 | ENSG00000158014 |
| SMIM24 | Small integral membrane protein 24 | 1.25301892 | 23.47494696 | 1.26551E-06 | ENSG00000095932 |
| RORC | RAR-related orphan receptor C | 1.621731103 | 23.41211242 | 1.30753E-06 | ENSG00000143365 |
| CLEC4F | C-type lectin domain family 4, member F | 1.905689525 | 23.13627604 | 1.50916E-06 | ENSG00000152672 |
| FOLH1 | Folate hydrolase (prostate-specific membrane antigen) 1 | 1.593863663 | 23.09609472 | .000001541 | ENSG00000086205 |
| PGC | Progastricsin (pepsinogen C) | -1.923972415 | 22.99096472 | 1.62765E-06 | ENSG00000096088 |
| FOSL1 | FOS-like antigen 1 | -2.400350289 | 22.87060113 | 1.73282E-06 | ENSG00000175592 |
| ABCC6 | ATP-binding cassette, subfamily C (CFTR/MRP), member 6 | 1.701645886 | 22.74240918 | 1.85234E-06 | ENSG00000091262 |
| SLC52A1 | Solute carrier family 52 (riboflavin transporter), member 1 | 1.330488729 | 22.76413548 | 1.83152E-06 | ENSG00000132517 |
| ERICH4 | Glutamate-rich 4 | 1.152189244 | 22.77999852 | 1.81646E-06 | ENSG00000204978 |
| PNLIPRP2 | Pancreatic lipase-related protein 2 | 1.430493624 | 22.75890815 | 1.83651E-06 | ENSG00000266200 |
| ASAH2 | N-acylsphingosine amidohydrolase (nonlysosomal ceramidase) 2 | 1.367297002 | 22.67467775 | 1.9188E-06 | ENSG00000188611 |
| PDZD7 | PDZ domain containing 7 | 1.19335086 | 22.6056947 | 1.98894E-06 | ENSG00000186862 |
| DCSTAMP | Dendrocyte-expressed 7 transmembrane protein | 4.290165257 | 22.35510009 | 2.2661E-06 | ENSG00000164935 |
| ABCG8 | ATP-binding cassette, subfamily G (white), member 8 | 1.334210188 | 22.32450691 | 2.30249E-06 | ENSG00000143921 |
| RAB17 | RAB17, member RAS oncogene family | 1.246564272 | 22.24989867 | 2.39371E-06 | ENSG00000124839 |
| CA7 | Carbonic anhydrase VII | 1.453047121 | 22.28269301 | 2.35318E-06 | ENSG00000168748 |
| KCNH6 | Potassium channel, voltage-gated eag-related subfamily H, member 6 | 1.685088587 | 22.25545876 | 2.38679E-06 | ENSG00000173826 |
| ESPN | Espin | 1.133210251 | 22.06396747 | 2.63714E-06 | ENSG00000187017 |
| C10orf99 | Chromosome 10 open reading frame 99 | 2.465624328 | 22.05917803 | 2.64373E-06 | ENSG00000188373 |
| CLDN23 | Claudin 23 | 1.045566126 | 22.05403209 | 2.65082E-06 | ENSG00000253958 |
| SLC26A3 | Solute carrier family 26 (anion exchanger), member 3 | 1.494972698 | 22.01805961 | .000002701 | ENSG00000091138 |
| BTNL3 | Butyrophilin-like 3 | 1.265622259 | 21.86960556 | 2.9182E-06 | ENSG00000168903 |
| B4GALNT2 | β-1,4-N-acetyl-galactosaminyl transferase 2 | 2.203101248 | 21.8177065 | 2.9982E-06 | ENSG00000167080 |
| MEP1B | Meprin A, β | 1.442428396 | 21.74734893 | 3.11019E-06 | ENSG00000141434 |
| ENTPD8 | Ectonucleoside triphosphate diphosphohydrolase 8 | 1.275503513 | 21.74791285 | 3.10928E-06 | ENSG00000188833 |
| OSBP2 | Oxysterol binding protein 2 | 1.073037668 | 21.62906423 | .000003308 | ENSG00000184792 |
NOTE. RNA sequencing analysis identified the top 100 up- and down-regulated genes that were affected by prolonged absence of mechanoluminal stimulation in human patients with ileostomies.
ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; CFTR/MRP, cystic fibrosis transmembrane conductance regulator/multidrug resistance-associated protein; cGMP, cyclic guanosine monophosphate; EC, classic E basic helix-loop-helix protein; FERM, 4.1 protein/ezrin/radixin/moesin; FOS, Fos proto-oncogene, AP-1 transcription factor subunit; GCN5, gene control of amino acid synthesis protein 5-like 2; HGNC, HUGO Gene Nomenclature Committee; MAM, meprin/A-5 protein/ receptor protein-tyrosine phosphatase mu; RAR, retinoic acid receptor; RAS, retrovirus-associated DNA sequences; TRHDE, thyrotropin releasing horomone degrading enzyme.
Primary and Secondary Antibodies
| Antibody | Species | Company | Catalog no | Dilution |
|---|---|---|---|---|
| Primary | ||||
| Mucin 2 (MUC2) | Rabbit | Santa Cruz Biotechnology (Dallas, TX) | sc-15334 | 1:100 |
| Chromogranin A (CHGA) | Rabbit | Abcam (Cambridge, MA) | ab15160 | 1:100 |
| Lysozyme (LYZ) | Rabbit | Dako Cytomation | A0099 | 1:100 |
| E-cadherin (E-CAD) | Mouse | BD Transduction (San Jose, CA) | 610181 | 1:100 |
| Ki67 | Rabbit | Thermo Scientific (Waltham, MA) | RM-9106-S1 | 1:100 |
| Proliferating cell nuclear antigen | Mouse | Vector Laboratories | VP-P980 | 1:100 |
| Cleaved caspase 3 (CC3) | Rabbit | Cell Signaling Technologies (Danvers, MA) | 9661 | 1:50 |
| LGR5 | Rabbit | Miltenyi (San Diego, CA) | 130-104-945 | 1:200 |
| Phosphorylated STAT3 (pSTAT3) | Rabbit | Cell Signaling Technologies | 9145 | 1:1000 |
| STAT3 | Rabbit | Cell Signaling Technologies | 4904 | 1:1000 |
| Actin (clone AC-15) | Mouse | Sigma (St. Louis, MO) | A1978 | 1:10,000 |
| OLFM4 | Rabbit | Abcam | AB85046 | 1:200 |
| SOX9 | Rabbit | Millipore (Billerica, MA) | AB5535 | 1:200 |
| Secondary | ||||
| Alexa Fluor anti-rabbit 488 | Goat | Life Technologies (Carlsbad, CA) | Z25302 | 1:200 |
| Alexa Fluor anti-rabbit 555 | Goat | Life Technologies | A21429 | 1:200 |
| Biotinylated anti-rabbit | Goat | Jackson ImunoResearch (West Grove, PA) | 111-066-047 | 1:1000 |
| DTAF-conjugated streptavidin | Jackson ImunoResearch | 016-101-084 | 1:500 | |
| IRDye 680LT anti rabbit | Donkey | LI-COR (Lincoln, NE) | 926-68023 | 1:10,000 |
| IRDye 800CW anti-mouse | Donkey | LI-COR | 926-32212 | 1:10,000 |
NOTE. The name, source, catalog number, and dilution are provided for the primary and secondary antibodies included in the study.
DTAF, dichlorotriazinyl aminofluorescein.
qPCR Primer List
| Gene | Primer sequence |
|---|---|
| LGR5 | F: GCCCTTCCACGATGCCAAAG |
| CCND1 | F: GCCGAGAAGCTGTGCATC |
| C-MYC | F: GCTGCTTAGACGCTGGATTT |
| REG1b | F: GCCTCCATGACCCAAAAA |
| IL1B | F: TACCTGTCCTGCGTGTTGAA |
| COL2A1 | F: GTGAACCTGGTGTCTCTGGTC |
| NAT8 | F: GGACCAGGGCTACAGTGAAGT |
| IL22 | F: CAACAGGCTAAGCACATGTCA |
| FMO1 | F: TTGGCACCAGAAATTACAAGAG |
NOTE. Forward (F) and reverse (R) primer sequences for genes of interest in the study are provided.
Figure 2Absence of mechanoluminal stimulation decreases villus height, crypt depth, and crypt proliferation. (A–D) H&E staining and morphometric analysis of matched fed vs unfed intestine from each patient. (E–S) Immunofluorescence staining and quantification of (E–G) MUC2+ goblet cells per hemivillus, (H–J) chromagranin A (CHGA)+ enteroendocrine cells per hemivillus, (K–M) LYZ+ Paneth cells per crypt with E-cadherin (Ecad) counterstain, (N–P) percentage of Ki67+ cells in crypts, and (Q–S) CC3+ cells per 10 villi. Images are representative pairs from different patients (n = 5–7 pairs of intestine for quantification). Images were obtained on an upright Leica DM5500B immunofluorescence microscope using Leica Suite Advanced Fluorescence (LAS AF) 6000 software, processed with ImageJ software. Scale bars: 100 μm. *P < .05. Grey bars on plots indicate median with 95% confidence interval.
Figure 3Genome-wide analysis of fed and unfed intestine shows significant changes in unfed intestine. (A) Principal component analysis of 5 matched unfed (white) and fed (black) intestinal pairs analyzed by RNA sequencing. Two principal components were analyzed with the percentage of variability explained by each component shown. (B) Volcano plot of sequenced genes. On the x-axis, log2 transformed counts per million (CPM) graphs the number of reads per gene. The average log2 transformed fold change of each gene is plotted on the y-axis with a positive fold change indicating increased expression in the unfed limb. Each dot represents 1 gene. Red dots are those with a false-discovery rate corrected P value < .05. Blue lines at y = 1.5 and -1.5 indicate the cut-off value chosen for meaningful fold change. (C) Correlation of RNA sequencing determined log2 fold changes with qPCR-based fold changes for 7 selected genes of interest.
Figure 4Gene Ontology enrichment analysis of genes up-regulated and down-regulated by absence of mechanoluminal stimulation indicates significantly affected biological processes. Gene Ontology (GO) analysis of up-regulated genes (A) over-represented and (B) under-represented by withdrawal of mechanoluminal stimulation and (C) down-regulated genes over-represented by the absence of mechanoluminal stimulation with a false-discovery rate corrected P value < .05. Over-represented pathways are shown, with circle size proportional to the number of genes included in the GO term. P value is represented by the color scale. Arrows indicate hierarchical relationships with most generalized terms at the base.
Figure 5Absence of mechanoluminal stimulation increases (A and B) Quantification and in situ hybridization of LGR5 ISCs within the crypts of fed and unfed intestine. Inset: High-magnification photographs label LGR5-positive in situ hybridization with purple arrows. qPCR comparison of (C) LGR5, (D) CCND1, and (E) MYC mRNA expression between 6 and 7 pairs of matched fed vs unfed intestine with outliers excluded. (F) Representative images of Western blot analysis of STAT3 phosphorylation from 3 pairs of matched tissue. Images were obtained on an upright Leica DM5500B immunofluorescence microscope using Leica Suite Advanced Fluorescence (LAS AF) 6000 software, processed with ImageJ software. Scale bars: 50 μm. *P < .05. Grey bars on plots indicate median with 95% confidence interval.
Figure 6Global decrease of LGR5+, SOX9+, and OLFM4+ intestinal stem cell populations occurs in the absence of mechanoluminal flow. (A–H) Quantification and immunofluorescence staining of LGR5+ rapidly cycling intestinal stem cells per crypt with proliferating cell nuclear antigen counterstain in fed vs unfed intestine. (C and F) LYZ+ Paneth cells with E-cadherin (Ecad) counterstain of same crypt shown in panels A and D, respectively, for comparison. (I–N) Quantification and immunofluorescence staining of SOX9 and OLFM4 intestinal stem cells per crypt in fed vs unfed intestine. Images were obtained on an upright Leica DM5500B immunofluorescence microscope using Leica Suite Advanced Fluorescence (LAS AF) 6000 software, processed with ImageJ software. Scale bars: (B, C, E, and F) 50 μm, and (A, D, I, J, L, and M) 100 μm. *P < .05. Grey bars on plots indicate median with 95% confidence interval. PCNA, proliferating cell nuclear antigen.
Figure 7Heatmap representation of biological processes of interest shows differential expression of significant genes between fed and unfed intestine. (A–E) Heatmap representation of significantly different genes within biological processes of interest for the 5 pairs analyzed by RNA sequencing. One gene is graphed in each row and one intestinal sample is graphed in each column. Color represents the expression level with increased expression in green and decreased expression in magenta. (F–H) qPCR comparison of pro-proliferative inflammatory genes IL22, REG1B, and IL1B mRNA expression between 6 and 7 pairs of matched fed vs unfed intestine with outliers excluded. *P < .05. Grey bars on plots indicate median with 95% confidence interval.